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Peter Alexander7, Thomas Vogt4,5, Xiaowei Xu8, Wei-Ting Hwang9, Melissa Lieu10, Eric Belser1, Rui Liu11,
Rajasekharan Somasundaram1, Meenhard Herlyn1 and Russel E. Kaufman1
Tumor-associated macrophages (TAMs) have essential roles in tumor progression and metastasis. Tumor cells
recruit myeloid progenitors and monocytes to the tumor site, where they differentiate into TAMs; however, this
process is not well studied in humans. Here we show that human CD7, a T-cell and NK cell receptor, is highly
expressed by monocytes and macrophages. Expression of CD7 decreases in M-CSF-differentiated macrophages
and in melanoma-conditioned medium–induced macrophages (MCMI/Mf) in comparison to monocytes. A
ligand for CD7, SECTM1 (secreted and transmembrane protein 1), is highly expressed in many tumors, including
melanoma cells. We show that SECTM1 binds to CD7 and significantly increases monocyte migration by
activation of the PI3K (phosphatidylinositol 30-kinase) pathway. In human melanoma tissues, tumor-infiltrating
macrophages expressing CD7 are present. These melanomas, with CD7-positive inflammatory cell infiltrations,
frequently highly express SECTM1, including an N-terminal, soluble form, which can be detected in the sera
of metastatic melanoma patients but not in normal sera. Taken together, our data demonstrate that CD7 is
present on monocytes and tumor macrophages and that its ligand, SECTM1, is frequently expressed in
corresponding melanoma tissues, possibly acting as a chemoattractant for monocytes to modulate the melanoma
microenvironment.
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INTRODUCTION
Tumor-associated macrophages (TAMs) are a major component
of tumor stroma, and they modulate the tumor microenviron-
ment by increasing tumor initiation and growth, remodeling the
extracellular matrix, promoting angiogenesis, and suppressing
anti-tumor immunity. High numbers of macrophages are asso-
ciated with a poor prognosis in a variety of cancers, including
breast cancer and colon cancer (Torisu et al., 2000; Solinas
et al., 2009; Qian and Pollard, 2010). In melanoma, it has been
reported that macrophages are essential for UVR-induced
melanomagenesis in a neonatal mouse model (Zaidi et al.,
2011; Handoko et al., 2013). Furthermore, macrophages
produce many factors that suppress T-cell functions and
increase tumor angiogenesis, invasion, and metastasis (Varney
et al., 2005; Gazzaniga et al., 2007; Wang et al., 2012a). More
importantly, it has been reported that the numbers of macro-
phages in melanoma tissues correlate with poor prognosis in
early-stage melanomas (stage I, II; Jensen et al., 2009).
Macrophages have been classified into M1 and M2 macro-
phages depending on the environmental cues. M1 macrophages
are polarized by lipopolysaccharide and IFN-g and produce
high levels of IL-12 and low levels of IL-10, while M2
macrophages are polarized by IL-4 and produce low levels of
IL-12 and high levels of IL-10. It is generally accepted that TAMs
resemble M2 macrophages and exert pro-tumor activity. How-
ever, recent studies indicated that TAMs are highly heteroge-
neous and may have mixed phenotypes of M1 and M2
macrophages. Our previous study demonstrated that mela-
noma-conditioned medium–induced macrophages (MCMI/Mf)
express both M1 and M2 macrophage markers but exert M2
macrophage functions, such as immune suppression and
enhancement of melanoma cell invasion (Wang et al., 2012a).
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Macrophages are differentiated from monocytes. Tumor
cells can promote this by elaborating many factors, including
M-CSF and CCL-2 (C-C motif chemokine ligand 2), that recruit
blood monocytes and contribute to their differentiation to
macrophages (Pixley and Stanley, 2004; Duluc et al., 2007;
Roca et al., 2009). However, other unknown factors may also
have roles in monocyte migration.
CD7 is a 40-kDa type I transmembrane glycoprotein, which
is found on T cells, natural killer (NK) cells, myeloid precursor
cells, and plasmacytoid dendritic cells, as well as a variety of
leukemia cells (Sempowski et al., 1999; Stillwell and Bierer,
2001; Milush et al., 2009). Despite extensive analysis, no
dominant biological process or disease has been discovered
that results from CD7 loss of function or overstimulation in
humans. Loss of CD7 in a murine model system showed only
a mild effect, mainly a reduction of regulatory T cells and a
resistance to lipopolysaccharide-induced septic shock. CD7 is
also expressed by early hematopoietic precursors, including
the common lymphoid progenitor, but it has no defined role in
blood cell formation. It has been reported that CD7 expression
is lost when cells differentiate from myeloid precursor cells to
monocytes (Wells et al., 2003).
A potentially important role for CD7 is activation by its
ligand SECTM1 (secreted and transmembrane protein 1) in the
co-stimulation and proliferation of T and NK cells (Lyman
et al., 2000; Wang et al., 2012b). SECTM1 is a 27-kDa type I
transmembrane protein whose soluble form is a ligand for
CD7. SECTM1 is expressed by a number of normal cell types,
including neutrophils, dendritic cells, and epithelial cells. It is
also highly expressed by breast and prostate cancer cell lines
and by some myeloid leukemias (Slentz-Kesler et al., 1998;
Lam et al., 2005; Wang et al., 2012b). However, the biological
significance of SECTM1 expression in tumors is unknown. The
expression of SECTM1 can be upregulated by IFN-g in many
cell types, including thymic epithelial cells, monocytes, and
dendritic cells, as well as some types of tumor cells (Lam et al.,
2005; Huyton et al., 2011; Wang et al., 2012b)
Anecdotal evidence has suggested that CD7 might be
expressed by monocytes. We have performed microarray
analyses of monocytes and different types of macrophages,
which demonstrated definitively that CD7 is expressed in
human monocytes but is downregulated in MCMI/Mf
(Wang et al., 2012a). In this study, we confirmed that CD7
is expressed in human monocytes at both the RNA and
protein levels and to a lesser extent in M-CSF-differentiated
macrophages (M-CSF/Mf) and in MCMI-Mf. CD7 is expres-
sed only at a very low level in GM-CSF-differentiated
macrophages (GM-CSF/Mf).
Our analysis of the expression of the ligand for CD7 has
shown that SECTM1 is highly expressed in melanoma cell
lines compared with normal melanocytes and is induced by
IFN-a and Velcade. We demonstrated that SECTM1 activates
the phosphatidylinositol 30-kinase (PI3K)/AKT signaling path-
way in monocytes and increases monocyte migration in a
CD7-dependent manner. SECTM1 is not only expressed at
high levels in melanoma tissues but is also detectable by
western blotting in sera from metastatic melanoma patients
but not in normal sera. As melanoma tissues contain a
significant number of CD7-positive macrophages, SECTM1
may have a role in either attracting or activating monocytes in
melanomas. Therefore, the interaction of CD7 and SECTM1
may have a significant biological role in melanoma and may
affect the efficacy of melanoma therapies.
RESULTS AND DISCUSSION
CD7 is expressed in monocytes and macrophages
We have reported an in vitro system to differentiate monocytes
to macrophages using melanoma-conditioned media (Wang
et al., 2012a). Because it has been shown that myeloid-
derived suppressor cells (MDSC) express many markers similar
to macrophages and share many similar functions with TAMs
in human tumors (Nagaraj and Gabrilovich, 2010), we further
characterized MCMI/Mf to exclude the possibility of MDSC
contamination. We found that MCMI/Mf express CD16 and
HLA-DR, two markers that are negative for MDSC (Figure 1a).
MCMI/Mf also express a late-stage macrophage marker
(Figure 1b). Together, these data and our previous work
indicate that MCMI/f are highly similar to the TAMs.
To confirm the expression of CD7 in monocytes and
macrophages, we performed real-time PCR for CD7 on
monocytes, MCMI/Mf, M-CSF/Mf, and GM-CSF/Mf (Hume
and MacDonald, 2012). We found that mRNA levels for CD7
were expressed at a high level in monocytes, while expression
of CD7 was expressed at a lower level in M-CSF/Mf and
MCMI/Mf. A much lower level of CD7 expression was
detected in GM-CSF/Mf (Figure 1c). Next, we examined the
expression of CD7 at the protein level in monocytes, M-CSF/
Mf, GM-CSF/Mf, and MCMI-Mf by flow cytometric analysis
with the anti-CD7 antibody, 3A1, which was also used to stain
for cell surface expression of CD7 in T cells. Corresponding to
the RNA expression studies, CD7 was also expressed in
monocytes (Figure 1d), M-CSF/Mf, C8161/Mf, and 1205Lu/
Mf but not in GM-CSF/Mf (Figure 1e). Finally, we conducted
western blotting analysis with a novel rabbit anti-human CD7
mAb, which recognizes the C-terminal 25 amino acids of the
CD7 molecule. This peptide was used to produce the anti-
body, because it contains no homologous sequence in other
human molecules and staining of cells known to be negative
for CD7 expression by reverse transcriptase–PCR supports the
specificity of this antibody (data not shown). Consistent with
the flow cytometric analysis results, western blotting analysis
of purified monocytes and macrophages with this antibody
revealed an anticipated 40-kDa band, with the highest level of
CD7 expression in monocytes and the lowest level in GM-
CSF/Mf (Figure 1e).
Despite the widespread use of anti-CD7 antibodies, there
has not been a definitive study demonstrating CD7 expression
on monocytes and macrophages. In order to better understand
this, we used several other commercially available CD7
monoclonal antibodies to look for the expression of CD7 on
these cell types and, contrary to our results described above,
these antibodies did not detect the expression of CD7 in
monocytes. It is possible that those antibodies recognize
different epitopes or have a lower affinity than the CD7
antibodies used in this study. However, similar differences in
results with different anti-CD7 antibodies were also seen in
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studies to detect the expression of CD7 in T cells (Haynes,
1981). It is also possible that different epitopes of CD7 are
present in monocytes compared with T cells due to
modification(s) or clustering with other molecules. For
example, an anti-CD7 mAb, clone 3D9, does not recognize
intestinal intraepithelial lymphocytes, whereas most other
anti-CD7 antibodies recognize them (Russell et al., 1994).
Nonetheless, our data definitively demonstrate that CD7 is
expressed in monocytes, M-CSF/Mf, and MCMI/Mf and at
much lower levels or undetectable levels in GM-CSF/Mf,
suggesting that CD7 might have roles in modulating the
functions of monocytes and macrophages within the tumor
microenvironment.
SECTM1 is highly expressed in melanomas
We have previously reported that SECTM1 is expressed in
breast cancer and in prostate cancer cell lines (Slentz-Kesler
et al., 1998). Bioinformatics analysis of the Gene Expression
Omnibus database indicates that SECTM1 is also expressed in
other types of cancers, including melanomas (data not shown).
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Figure 1. Expression of CD7 by monocytes and macrophages. Expression of (a) CD16, HLA DR, and (b) the late-stage marker was analyzed by flow cytometry.
1205Lu-Mf were stained with the fluorescence-conjugated anti-CD16, HLA DR, and late-stage macrophage marker. (c) Real-time PCR was used to analyze the
expression of CD7 in monocytes, GM-CSF, M-CSF-differentiated macrophages, and C8161 (C68161-Mf) and 1205Lu (1205Lu-Mf) melanoma-conditioned
media-differentiated Mf. Samples were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase). (d) Monocytes, (e) M-CSF/Mf, M-CSF/Mf, C8161/
Mf, and 1205Lu/Mf were stained with the anti-human CD7 mAb, 3A1, followed by FITC-conjugated anti-mouse IgG staining for FACS analysis. Filled: isotype
control, black line: anti-CD7. (f) Western blotting analysis expression of CD7 in monocytes, GM-CSF/Mf, M-CSF/Mf, C8161/Mf, and 1205Lu/Mf. RAb11 was
used as a loading control.
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We further characterized the expression of SECTM1 in
melanoma cell lines and in cultured melanocytes by real-
time PCR. SECTM1 is highly expressed in many of the
melanoma cell lines analyzed and is particularly highly
expressed in WM793, WM98, and WM9 cells in
comparison with normal melanocytes (Figure 2a). Analysis
of protein expression of SECTM1 by western blotting was
generally consistent with the mRNA analysis, with expression
of SECTM1 (full length and the membrane-retained segment)
being higher in melanoma cells than in melanocytes
(Figure 2b). Flow cytometric analysis indicated that SECTM1
can be detected in WM98 and WM793 melanoma cells by
intracellular staining, but not by surface staining (Figure 2c,
and data not shown). Furthermore, confocal microscopy
analysis confirmed that SECTM1 was expressed more highly
in melanoma cells than in melanocytes, with the pattern being
perinuclear, but not on the cell surface (Figure 2d). This
expression pattern is similar to that of SECTM1 seen in primary
breast cancer lines (Slentz-Kesler et al., 1998). Interestingly,
we found that CD7 is not expressed in melanocytes but is
expressed in one of the eight melanoma cell lines, WM98
(Figure 2g). Furthermore, this cell line also expresses a high
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Figure 2. SECTM1 (secreted and transmembrane protein 1) is highly expressed in melanoma. (a) Relative amounts of SECTM1 mRNA expression were
determined by real-time reverse transcriptase–PCR in melanoma cells and melanocytes. Samples were normalized to GAPDH (glyceraldehyde-3-phosphate
dehydrogenase). (b) Western blotting analysis of SECTM1 expression in melanocytes and in melanoma cells. The upper band is the 27 kDa full-length SECTM1,
and the lower band is the membrane retention part of SECTM1. Heat-shock protein 90 (HSP90) was used as the loading control. (c) Expression of SECTM1
analyzed by flow cytometry. WM98 and WM793 cells were intracellularly stained with an anti-SECTM1 antibody. (d) Confocal analysis of SECTM1 expression
(green) in melanocytes and in 1205Lu melanoma cells. Topro-3 was used for nuclear staining (red color). Bar¼30mm. (e) WM35 and 1205Lu melanoma cells
were treated with increased concentrations of IFN-a for 6 hours. Intracellular staining was performed to measure the expression of SECTM1 by FACS analysis.
(f) 1205Lu cells were stimulated with the indicated concentration of proteasome inhibitors, MG-132 (left panel) and Velcade (PS-341, right panel) for 4 hours.
Intracellular staining was performed to measure the expression of SECTM1. (g) Cell lysates from melanocytes and melanoma cell lines were loaded and analyzed
by western blotting using a rabbit monoclonal anti-CD7 antibody. HSP90 was used as a loading control.
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level of SECTM1 compared with other melanoma cell lines
tested, indicating the potential for autocrine interaction
between SECTM1 and CD7 in melanoma cells.
Expression of SECTM1 is induced by IFN-a and proteasome
inhibitors
Our previous work demonstrated that the expression of
SECTM1 is induced by IFN-g in a STAT1 (signal transducer
and activator of transcription factor 1) transcription factor-
dependent manner (Wang et al., 2012b). As IFN-a has been
used as an immune adjuvant therapy for melanoma therapy,
and many genes that are regulated by IFN-g are also induced
by IFN-a through the activation of STAT1, we investigated
whether SECTM1 was also induced in melanoma cells by
IFN-a. As expected, flow cytometric analysis showed that
SECTM1 was strongly induced in 1205Lu and WM35
melanoma cell lines (Figure 2e).
It was noted that the pattern of expression of SECTM1
protein in melanoma cells was not fully consistent with the
mRNA levels (Figure 2a and b), which suggested that the
expression of SECTM1 might also be regulated at the post-
transcriptional level. Indeed, we demonstrated using flow
cytometric analysis that SECTM1 was significantly induced
after WM35 melanoma cells were treated with proteasome
inhibitors, MG-132 or Velcade (PS-341). Western blotting
analysis also indicated that MG132 induces SECTM1 expres-
sion in WM35 cells in a dose- and time-dependent manner
(Supplementary Figure S1 online). Velcade is a proteasome
inhibitor that is Food and Drug Administration approved for
treating multiple myeloma and has been used in clinical trials
for treating melanomas and breast cancer (Figure 2f). These
drugs would likely have an effect on SECTM1 expression and
could have a clinical effect on these tumors.
SECTM1 increases monocyte migration via binding to CD7
The high levels of expression of CD7 in monocytes and the
expression of SECTM1 in melanoma cells suggest that
SECTM1 may have a role in modulating the functions of
monocytes. We therefore performed a transwell assay to
determine the effects of SECTM1 on monocyte migration. As
shown in Figure 3a, the recombinant soluble extracellular
SECTM1 protein was a potent chemoattractant for monocytes,
though less effective compared with M-CSF, a major che-
moattactant for monocytes. SECTM1-induced monocyte
migration was significantly blocked by the anti-CD7 mAb
3A1 (Figure 3a). We examined the ability of the anti-CD7
mAb to block the monocyte migration induced by supernatant
from C8161 cells engineered to overexpress the soluble form
of SECTM1 (sSECTM1) (Supplementary Figure S2 online). As
shown in Figure 3b, blockade of CD7 significantly inhibited
melanoma cell–derived SECTM1-induced monocyte migra-
tion. Finally, we used conditioned media from WM98 cells
(SECTM1 positive) and C8161 cells (SECTM1 negative) to
conduct a monocyte migration assay. We did not find a
significant difference in monocyte migration (data not shown).
By themselves, these data comparing the SECTM1 expressing
and non-expressing cell lines contribute little to our under-
standing of the role of SECTM1, as we do not know all the
factors expressed in these cells that may make them chemoat-
tractant. Also, the comparison of the naturally expressing
SECTM1 with the cell lines engineered to express SECTM1 is
difficult to interpret, because we know that cells that naturally
express SECTM1 do not demonstrate surface expression,
whereas those engineered to express SECTM1 usually can be
detected with antibody to SECTM1 (data not shown). Cells
engineered to express SECTM1 usually express a higher level
and this high amount of SECTM1 may be needed to augment
monocyte chemoattraction in the face of existing potent
factors (Figure 3a). As SECTM1 is significantly induced by
IFN-a and Velcade, SECTM1-induced monocyte migration
may be most noticeable during exposure to those inducing
agents. Therefore, our data indicate that SECTM1 is a mono-
cyte chemoattractant mediated by binding to CD7 and may be
particularly active under conditions when it is expressed at
high levels.
SECTM1-induced monocyte migration is dependent
on the activation of the PI3K pathway but not the
MAPK (mitogen-activated protein kinase) pathway
Ligation of CD7 results in activation of the PI3K pathway in
T cells (Ward et al., 1995; Stillwell and Bierer, 2001). We
investigated the downstream signaling pathway activated by
SECTM1. We found that SECTM1 strongly activated AKT
signaling but not extracellular signal–regulated kinase (ERK)
signaling (Figure 3c). To examine the relevance of activating
the PI3K/AKT pathway on SECTM1-induced monocyte migra-
tion, we examined the chemoattractive effect of SECTM1 in
the presence of a MEK (MAPK/ERK kinase) inhibitor,
GSK110212, and two PI3K/AKT inhibitors, LY294002 and
AZD8055, to block the kinase cascade at a dose that can
inhibit signaling but does not induce monocyte death (data not
shown). We found that blocking the AKT pathway was able to
inhibit SECTM1-induced monocyte migration, whereas no
significant effect was observed with the MEK inhibitors
(Figure 3d, data not shown). Consistent with these migration
results, blockade of the AKT pathway with AZD8055 dimin-
ished SECTM1-induced activation of AKT signaling
(Figure 3e). Our data suggest that SECTM1 activates the PI3K
pathway to increase monocyte migration in a PI3K/AKT-
dependent manner. As the AKT signaling pathway is also
important for monocyte growth and survival, and SECTM1 has
been shown to increase T and NK cell proliferation, we tested
whether this also occurred in monocytes. MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium) proliferation assay indicated that
SECTM1 induced no significant increase in monocyte prolif-
eration (Figure 3f). Furthermore, SECTM1 stimulation did not
affect cell death by flow cytometric analysis of Annexin V
and 7-AAD (7-aminoactinomycin D) staining (Figure 3g).
Our finding that CD7 is expressed in monocytes, TAMs,
M-CSF/Mf, and TCIM-Mf, but not in GM-CSF/Mf, and
the broad expression of its ligand SECTM1 suggests that
SECTM1 activation via CD7 may have a significant role in
the tumor microenvironment and may have a role in other
diseases associated with monocytes and macrophages. Also,
activation of the PI3K pathway modulates many functions of
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monocytes/macrophages (Bhatt et al., 2002; Olieslagers et al.,
2011), suggesting a role for SECTM1/CD7 interaction in other
monocyte/macrophage functions.
CD7 is expressed in patient melanoma tissues
The co-expression of SECTM1 and CD7 in tumor tissues
would provide additional evidence of the potential for a
significant biological interaction. Therefore, we examined
melanoma tissues for CD7 expression by TAMs with the use
of immunohistochemistry. We found that some CD7-positive
cells had typical macrophage morphology, with an abundant,
slightly foamy cytoplasm and bland centrally localized nuclei
(upper panel, Figure 4a). We also found that CD7 was
expressed in lymphoid cells (lower panel, Figure 4a). Confocal
analysis indicated that CD7-positive cells expressed a specific
TAM marker, CD163 (Figure 4b). As TAMs have been
demonstrated to be a marker for a poor prognosis in
melanomas (Torisu et al., 2000; Jensen et al., 2009), it is
likely that CD7-positive macrophages can also be used as a
prognostic marker for melanoma patients.
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Figure 3. SECTM1 (secreted and transmembrane protein 1) increases monocyte migration through activation of the PI3K pathway. (a) SECTM1 increases
monocyte migration in a transwell assay. Monocytes were added to the upper chamber, and increasing concentrations of recombinant SECTM1 protein were
added to the lower chamber. M-CSF was used as a positive control and an anti-CD7 monoclonal Ab (10mg ml 1) was used to block migration. Migration was
evaluated after 18 hours of incubation by counting stained migrating cells on the lower side of the filter. ***Po0.001. (b) Monocytes from a healthy donor were
added to the upper chamber of the transwell, and conditioned medium from SECTM1 over-expressing WM35 cells was used as the chemoattractant. Anti-CD7
antibodies (10mg ml1) were used to block SECTM1-induced monocyte migration. Migration was evaluated after 18 hours of incubation by counting stained
migrating cells on the lower side of the filter. Results are reported as migration index (fold increase over control). Data represent means±SD of four independent
experiments. ***Po0.01. (c) Monocytes were seeded in serum-free RPMI1640 medium for 16 hours and were then stimulated with the indicated amount of
SECTM1 for 20 minutes. Cells were lysed for western blotting analysis. (d) SECTM1-induced monocyte migration is dependent on the MAPK (mitogen-activated
protein kinase) and phosphatidylinositol 30-kinase (PI3K) pathways. Migration assay was conducted as in a. PI3K inhibitor AZD8055 (AZD, 2mM) and LY3940002
(Ly, 5mM) were used to block the PI3K pathway. ***Po0.001. (e) Monocytes were seeded in serum-free RPMI1640 medium for 16 hours and were then stimulated
with SECTM1 (20ng ml1) and AZD8055 (2mM) for 20 minutes. Cells were lysed for western blotting analysis. (f) Monocytes were cultured in the indicated
concentration of SECTM1 for 3 days. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay was used to
determine cell growth. (g) Monocytes were cultured with or without SECTM1 (20 ng ml1) for 3 days. Flow cytometric analysis of Annexin V and 7-AAD
(7-aminoactinomycin D) staining was used to determine cell death. ERK, extracellular signal–regulated kinase; OD, optical density.
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SECTM1 is highly expressed in patient melanoma tissues and can
be detected in sera from metastatic melanoma patients
We have demonstrated that SECTM1 expression can be
induced in cell lines. To better understand the expression of
SECTM1 in tumor tissues, we compared the expression of
SECTM1 in primary human melanoma specimens with that
seen in melanoma cell lines. We performed immunohisto-
chemical analysis of melanoma samples in a tissue array
consisting of 296 human primary melanomas of different
tumor stages, 25 dermal and 24 compound melanocytic nevi,
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Figure 4. Expression of CD7 and SECTM1 (secreted and transmembrane protein 1) melanoma tissues. (a) Immunohistochemical analysis of CD7 expression in
melanoma lesions. Arrow indicates CD7-positive macrophages. Red arrows: macrophage-positive cells. Blue arrows: lymphocyte-positive cells. Bar¼ 50mm.
(b) Confocal analysis of the co-expression of CD7 with CD163 in melanoma lesions. Red color: CD7-positive cells. Green color: CD163-positive cells. Blue color:
DAPI (4,6-diamidino-2-phenylindole) was used to stain cell nuclei. Bar¼100mm. (c) Representative images of the expression of SECTM1 in melanocytic nevus,
primary melanoma, and melanoma metastasis lesion as noted. Immunohistochemical analysis was conducted to analyze SECTM1 expression in paraffin-
embedded sections of the human tissue microarray. Bar¼ 50mm. (d) Summary of the percentage of SECTM1-positive samples in melanocytic nevus, primary
melanoma, and melanoma metastasis lesion. (e) Kaplan–Meier plot of event-free survival in melanomas with or without the expression of SECTM1. Log-rank test
P-value¼ 0.14. (f) Serum samples from healthy donors and metastatic melanoma patients were used for detecting SECTM1 expression by western blotting analysis.
A non-specific band was used as a loading control.
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and 35 cutaneous metastases from melanomas. Clinically
normal dermal nevi with little or no inflammatory cell
infiltrate showed particularly low SECTM1 expression (92%
negative), whereas many non-inflammatory cells in com-
pound nevi that had high levels of inflammatory cell infiltra-
tion expressed SECTM1 (72% negative). We found that 37% of
the primary melanoma samples had SECTM1 expression,
while 75% of cutaneous metastatic samples were SECTM1
positive (Figure 4c and d). We did not detect expression of
SECTM1 in normal skin tissues (Supplementary Figure S4
online). These data demonstrate that expression of SECTM1
is increased in primary melanomas and to a greater degree in
metastatic lesions compared with benign nevus lesions. We
further investigated the clinical implication of expression of
SECTM1 in melanomas. Kaplan–Meier methods and Cox
regression analysis were used to analyze the relationships
between the patient’s event-free survival and the expression of
SECTM1 in early stage (UICC (Union Internationale Contre le
Cancer) stage I, II) melanomas (N¼136, SECTM1 (þ )¼ 40,
SECTM1 ( )¼ 96). After adjusting for UICC stage and depth
of the tumor, our data suggested that patients with SECTM1
expression had shorter event-free survival compared with
those without SECTM1 expression, but it did not reach
statistical significance (hazards ratio¼ 1.98, 95% confidence
interval (0.81, 4.41), P¼ 0.14) (Figure 4e). Interestingly, we
observed a considerable increase in SECTM1 expression at
sites where melanoma tumors had been infiltrated by immune
cells. We observed that 64.5% of the 172 melanoma samples
with inflammatory infiltrations showed significant SECTM1
signals (Supplementary Figure S5a online). A similar expres-
sion pattern was seen in primary breast cancer tissues (Supple-
mentary Figure S5b online). This is likely due to SECTM1
being upregulated by IFN-g or IFN-a secreted by inflammatory
cancer stromal cells, such as T cells (Lam et al., 2005; Huyton
et al., 2011; Wang et al., 2012b).
As the N-terminus of SECTM1 is expressed as a soluble
form (Slentz-Kesler et al., 1998; Wang et al., 2012b), we
examined the expression of SECTM1 in sera from healthy
donors and from metastatic melanoma patients. We detected
only very low, if any, SECTM1 expression in sera from healthy
donors but found that SECTM1 was detected in all 14
metastatic melanoma patient serum samples (Figure 4f).
Considering the broad expression pattern of SECTM1, we
cannot exclude that SECTM1 is derived from immune cells
that may be stimulated by growth factors from tumor cells
rather than the tumor cells alone. Regardless, SECTM1
potentially may be used as a prognostic biomarker for
melanoma patients. The ability to detect the soluble form of
SECTM1 from a variety of tumors broadens its potential as a
biomarker for cancers. In fact, the soluble form of SECTM1 is
also detected in serum samples from ovarian cancer patients
and is one of the top five candidate biomarkers for ovarian
cancers (Kulasingam et al., 2010).
In this study, we have shown conclusively that CD7, one of
the most commonly used T and NK cell markers, is also
expressed in the mature monocyte/macrophage lineage and is
a chemoattractant receptor for its ligand SECTM1, which is
highly expressed in melanoma cells. SECTM1 is also induced
by IFN-a and by proteasome inhibitors. The ligation of CD7 by
SECTM1 strongly activates the PI3K pathway, which is
sufficient for SECTM1-induced monocyte migration. We
further demonstrate that CD7 is expressed in melanoma TAMs
and SECTM1 is highly expressed in metastatic melanoma
tissues, raising the possibility that the interaction between
SECTM1 and CD7 might have critical roles in modulating the
tumor microenvironment by attracting monocytes or macro-
phages. Blocking their interaction may be a potential novel
strategy for melanoma therapy. Finally, we show that SECTM1
can be detected in sera from melanoma patients but not
normal donors, raising the possibility that SECTM1 can be a
useful serum biomarker for melanoma.
MATERIALS AND METHODS
Reagents
The recombinant human secreted form of SECTM1 (sSECTM1) was
from Abpro Corporation (Lexington, MA). Anti-SECTM1 A1 mono-
clonal and anti-human CD7 3A1 hybridomas were gifts from Dr
Barton F. Haynes (Duke University). Antibodies were made by the
Wistar Hybridoma core facility. The rabbit anti-human SECTM1
2816 antibody was made in our lab using full-length SECTM1 as the
antigen and can recognize the three forms of SECTM1 (full length,
soluble and the membrane-retained segment). Anti-phospho-ERK,
total ERK, phospho-AKT, total AKT, phospho-RSK90, Rab11, HSP90,
and vinculin antibodies were from Cell Signaling (Swedesboro, NJ).
M-CSF, GM-CSF, and IFN-a were from R&D Systems (Minneapolis,
MA). MG132 and Velcade were from Calbiochem (Billerica, MA).
MTS (inner salt) was from Sigma (Waltham, MA). Annexin–PE
apoptosis detection kit was from BD Biosciences (San Jose, CA).
Cell cultures
The culture conditions for melanocytes and melanoma cells were as
previously described (Wang et al., 2012a).
Differentiation of monocytes to macrophages
Monocytes were from the AIDS Research Human Immunology
Core at the University of Pennsylvania, Philadelphia, PA. To generate
M-CSF/Mf, GM-CSF/Mf, or MCMI-Mf, monocytes were incubated
in the presence of complete RPMI1640 medium with 10 ng ml 1
M-CSF or 10 ng ml 1 GM-CSF or melanoma-conditioned media from
1205Lu and C8161 melanoma cells for 7 days. Half of the medium in
each culture was replaced with fresh medium at day 3. See details in
Wang et al. (2012a).
Monocyte proliferation and apoptosis
To assess the effect of SECTM1 on monocyte proliferation and
survival, 5 104 monocytes were cultured in RPMI 1640 medium
containing 5% fetal bovine serum (FBS) with or without SECTM1 for 3
days. Cell proliferation was determined by MTS assay. Flow cyto-
metric analysis of Annexin V–PE, and 7-AAD staining was used to
determine cell death according to the manufacturer’s instructions.
Real-time PCR
Total RNAs were isolated using an RNeasy Mini kit (Qiagen,
Germantown, MD). cDNAs were prepared using oligo(dT) primers
and Superscript reverse transcriptase (Invitrogen, Carlsbad, CA). Real-
time reverse transcriptase–PCR was conducted using an ABI Prism
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7000 using SYBR Green PCR Master Mix (Applied Biosystems,
Grand Island, NY). For SECTM1 expression, real-time PCR was
conducted using the Taqman assay according to the company’s
product instructions. All reagents were from Applied Biosystems.
For CD7 expression, real-time PCR was conducted using a SYBR
Green Kit (Applied Biosystems) with the following primers: Human
CD7: forward, 50-ACAGAAGGACCACCAGTAGCCA-30, and reverse,
50-GGTGCTTCATAAAGTCCTGGACC-30. GAPDH (glyceraldehyde-
3-phosphate dehydrogenase): forward, 50-GGCTGAGAACGGGAA
GCTTGTCA-30, and reverse, 50-CGGCCATCACGCCACAGTTTC-30.
The primers were designed according to the software for quantitative
real-time PCR (Roche, Pleasanton, CA). All real-time PCR was
performed using an initial reaction at 95 1C for 5 minutes, followed
by 40 cycles of 95 1C for 30 seconds, 58 1C for 30 seconds, 72 1C for
30 seconds, and then extension for 10 minutes at 72 1C.
Flow cytometry
Monocytes and macrophages were stained with the anti-human CD7
3A1 mAb followed by FITC-conjugated anti-mouse IgG antibody for
detection of membrane CD7. Intracellular staining of SECTM1 was
done as described previously (Wang et al., 2012b). Monocytes were
cultured in 10% FBS. Apoptosis assay were conducted using Annexin
V and 7-AAD staining according to the manufacturer’s instructions
(BD Biosciences).
Western blotting analysis
Cell lysates were separated on 4–20% Tris-glycine gels and were
transferred to nitrocellulose membranes. A rabbit anti-CD7 mAb from
Epitomics (Burlingame, CA) was used for detection of CD7 in
monocytes and macrophages. A rabbit anti-SECTM1 antibody was
used for detection of SECTM1 in melanocytes and melanoma cells.
Rab11, HSP90, or vinculin were used as loading controls.
Monocytes were incubated in serum-free RPMI medium for
2 hours. Cells were then stimulated by SECTM1 for 20 minutes and
were lysed to detect phospho-AKT, total AKT, phospho-ERK and total
ERK. Rab11 was used as a loading control.
Induction of SECTM1 by IFN-a and Velcade
1205Lu and/or WM35 melanoma cells were stimulated with Velcade
or IFN-a for 6 hours. Intracellular staining of SECTM1 was analyzed
by flow cytometry (Wang et al., 2012b).
Generation of the sSECTM1 overexpressing C8161 cell line
sSECTM1 was cloned into the phCMV3 vector (Genlantis, San Diego,
CA). The primers of sSECTM1 used for cloning were as follows:
forward primer, CCCAAGCTTACCATGCAGACCTGCCCCCTGGCA;
reverse primer, CGCGGATCCCCCAGTGTCAGGGGCGGAC. The
cloning vector was verified by DNA sequencing at The Wistar
Genomic Core Facility. For generating stable cell lines, C8161
melanoma cells were transfected with sSECTM1 using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. The
transfected C8161 cells were selected with G418 for 1 week, and
stable cell lines were verified by western blotting analysis with a
rabbit anti-human SECTM1 polyclonal antibody.
Monocyte migration
The migration assay was conducted with 24-well Transwell inserts
(5-mm pore size; Corning, Corning, NY). Freshly purified monocytes
in 1% FBS RPMI1640 medium were added in the upper chamber.
The lower chamber contained 0 (control), 5, 10, and 20 ng ml 1
sSECTM1. After overnight incubation, cells that had migrated in the
bottom chambers were counted for each transwell. The migration
index was calculated as the ratio of migrating cell numbers with
SECTM1 divided by those without SECTM1.
For the blocking assay using the CD7 antibody, monocytes were
preincubated with 10mg ml 1 anti-CD7 3A1 mouse antibody or an
isotype control for 10 minutes at room temperature. Migration was
then conducted as described above.
For the blocking assays using MEK inhibitor, GSK1120212 (0.5mM,
Selleck, Houston, TX) PI3K inhibitors, LY200094 (5mM, Sigma) and
AZD8055 (2mM, Selleck) were added to the Transwell. Migration was
then conducted as described above.
Human tissue samples
Obtainment of the archived formalin-fixed paraffin-embedded mate-
rial for the preparation of TMAs was approved by the Internal Review
Board of the Regensburg University Medical Center in adherence to
the declaration of Helsinki. According to statement E, II, 8 (2003,
‘‘further use of human tissue’’) of the German Central Ethical
Committee, informed consent was not required, because archived
and anonymized tissue was used that remained from surgery after
completion of essential diagnostic procedures. Melanoma tissues
were obtained from the University of Pennsylvania. The protocol
was approved by the institutional review board at the University of
Pennsylvania in adherence to the Helsinki Guidelines. Discarded
surgical specimens that are without identifying information or way to
trace it back to the subject were used in the experiments. As per the
NIH guideline, patient consent for experiments was not required to
use discarded material. Patient sera were obtained under institutional
review board–approved studies at the University of Pennsylvania. All
patients provided informed written consent. The breast cancer tissue
array was from IMGENEX (San Diego, CA) (commercial). The Wistar
Institute Institutional Review Board approved the use of all the above-
obtained tissues.
For immunohistochemical staining of SECTM1 in melanoma and
breast cancer tissues, human melanoma and breast cancer tissues
were deparaffinized through a series of xylene and graded alcohols,
boiled in 10 mM citrate buffer (pH 6.0) for 10 minutes at 92–95 1C and
equilibrated in phosphate-buffered saline (PBS) for antigen retrieval.
Subsequently, the slides were incubated with the rabbit anti-human
SECTM1 polyclonal antibody (1:100) or anti-human CD7 rabbit mAb
(1:100, Epitomics) overnight at 4 1C in a humidified chamber,
followed with a Vectastain Elite ABC Kit and Vector AEC substrate
(Vector Laboratories, Burlingame, CA).
Melanocytes and melanoma cells staining of SECTM1
Cells were fixed with 4% formaldehyde, and incubated with a rabbit
anti-human SECTM1 antibody (clone 2816) followed by incubation
with Alexa Fluor 488 secondary antibodies (Molecular Probes, Grand
Island, NY). Vectashield-mounting media containing DAPI (4,6-
diamidino-2-phenylindole) nuclear stain (Vector Laboratories) was used
to mount the slides with coverslips. Cells were counterstained with TO-
PRO3 (Invitrogen Life Technologies, Buffalo Grove, IL) and examined
using a Leica LSC P2 confocal microscope (Buffalo Grove, IL).
For immunofluorescence staining to examine the expression of
SECTM1 and the melanocyte marker HMB45, paraffin-embedded
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human foreskins derived from circumcisions of newborns were antigen
retrieved as described above. Tissues were incubated with the anti-
human SECTM1 antibody followed by incubation with Alexa Fluor 488
secondary antibodies (Molecular Probes). The slides were subsequently
incubated with the mouse anti-HMB45 (Abcam, San Francisco,
CA) antibody diluted in 0.5% BSA PBS for 2 hours at room tempera-
ture, followed by Alex 568-conjugated anti-mouse IgG mAb. Slides
were counterstained with TO-PRO3 (Invitrogen Life Technologies) and
examined using a Leica LSC P2 confocal microscope.
For immunofluorescence co-staining to examine the expression of
CD7 and CD163, primary melanoma tissues were antigen retrieved as
described above.
After incubation with the rabbit anti-CD7 mAb (1:200) at 4 1C
following Alex 568-anti-rabbit antibody for 30 minutes at room
temperature in a humidified chamber, the slides were subsequently
incubated with the mouse anti-CD163 (Abcam) antibody diluted in
0.5% BSA PBS for 2 hours at room temperature, followed by Alex
488-conjugated anti-mouse IgG mAb. Slides were counterstained
with DAPI (Invitrogen Life Technologies) and examined using a LSC
P2 confocal microscope.
Statistics
Descriptive statistics were computed for study variables. Kaplan–
Meier curves, log-rank test, and Cox proportion hazards regression
were used to analyze the relationships between event-free survival (in
month) and SECTM1 expression in melanomas. See detailed patient
information in references (Meyer et al., 2009, 2010, 2012).
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